ROCKET AF: Heart Failure Does Not Weaken the Case for Rivaroxaban TCTMD In patients with nonvalvular atrial fibrillation (A-fib), rivaroxaban stands as a valid alternative to warfarin regardless of heart failure status, according to findings derived from the ROCKET AF trial, published online May 30, 2013, ahead of print in ... |
